File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: Results of a comparative study in 96 Chinese patients

TitleTransarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: Results of a comparative study in 96 Chinese patients
Authors
Issue Date2003
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.html
Citation
American Journal Of Gastroenterology, 2003, v. 98 n. 5, p. 1181-1185 How to Cite?
AbstractOBJECTIVE: The efficacy of transarterial chemoembolization (TACE) in prolongation of survival is controversial. We conducted a comparative study to determine whether TACE treatment had any survival benefit for patients with unresectable hepatocellular carcinoma (HCC) and with relatively preserved liver function. METHODS: In all, 96 patients with unresectable HCC of Okuda stage I or II and Child-Pugh grade A or B were recruited. A total of 80 patients (group 1) who received TACE were compared to 16 patients (group 2) who were treated conservatively. RESULTS: The median survival time of group 1 patients was significantly longer than that of group 2 patients (31.2 vs 14.1 months respectively, p = 0,0126). The cumulative survival rates at 6 months, 1 yr, 2 yr, 3 yr, and 4 yr of group 1 compared to group 2 were as follows: 93.8% versus 62.5% (p = 0.002); 86.3% versus 62.5% (p = 0.023); 78.8% versus 50% (p = 0.017); 57.5% versus 50% (p = ns); and 51.3% versus 43.8% (p = ns), respectively. Tumor response was observed in 28% of patients receiving TACE. Patients with higher pretreatment albumin levels, lower pretreatment α-fetoprotein levels, and Okuda stage I disease were associated with a favorable response to TACE. CONCLUSION: TACE treatment improved survival in patients with unresectable HCC in the early stages and with relatively preserved liver function. © 2003 by Am. Coll. of Gastroenterology.
Persistent Identifierhttp://hdl.handle.net/10722/162694
ISSN
2015 Impact Factor: 10.383
2015 SCImago Journal Rankings: 3.946
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_US
dc.contributor.authorChan, AOOen_US
dc.contributor.authorWong, BCYen_US
dc.contributor.authorHui, CKen_US
dc.contributor.authorOoi, GCen_US
dc.contributor.authorTso, WKen_US
dc.contributor.authorYuan, HJen_US
dc.contributor.authorWong, DKHen_US
dc.contributor.authorLai, CLen_US
dc.date.accessioned2012-09-05T05:22:25Z-
dc.date.available2012-09-05T05:22:25Z-
dc.date.issued2003en_US
dc.identifier.citationAmerican Journal Of Gastroenterology, 2003, v. 98 n. 5, p. 1181-1185en_US
dc.identifier.issn0002-9270en_US
dc.identifier.urihttp://hdl.handle.net/10722/162694-
dc.description.abstractOBJECTIVE: The efficacy of transarterial chemoembolization (TACE) in prolongation of survival is controversial. We conducted a comparative study to determine whether TACE treatment had any survival benefit for patients with unresectable hepatocellular carcinoma (HCC) and with relatively preserved liver function. METHODS: In all, 96 patients with unresectable HCC of Okuda stage I or II and Child-Pugh grade A or B were recruited. A total of 80 patients (group 1) who received TACE were compared to 16 patients (group 2) who were treated conservatively. RESULTS: The median survival time of group 1 patients was significantly longer than that of group 2 patients (31.2 vs 14.1 months respectively, p = 0,0126). The cumulative survival rates at 6 months, 1 yr, 2 yr, 3 yr, and 4 yr of group 1 compared to group 2 were as follows: 93.8% versus 62.5% (p = 0.002); 86.3% versus 62.5% (p = 0.023); 78.8% versus 50% (p = 0.017); 57.5% versus 50% (p = ns); and 51.3% versus 43.8% (p = ns), respectively. Tumor response was observed in 28% of patients receiving TACE. Patients with higher pretreatment albumin levels, lower pretreatment α-fetoprotein levels, and Okuda stage I disease were associated with a favorable response to TACE. CONCLUSION: TACE treatment improved survival in patients with unresectable HCC in the early stages and with relatively preserved liver function. © 2003 by Am. Coll. of Gastroenterology.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/ajg/index.htmlen_US
dc.relation.ispartofAmerican Journal of Gastroenterologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAntineoplastic Agents - Administration & Dosageen_US
dc.subject.meshCarcinoma, Hepatocellular - Mortality - Pathology - Therapyen_US
dc.subject.meshChemoembolization, Therapeutic - Methodsen_US
dc.subject.meshCisplatin - Administration & Dosageen_US
dc.subject.meshContrast Media - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHepatic Arteryen_US
dc.subject.meshHumansen_US
dc.subject.meshInjections, Intra-Arterial - Methodsen_US
dc.subject.meshIodized Oil - Administration & Dosageen_US
dc.subject.meshLiver Function Testsen_US
dc.subject.meshLiver Neoplasms - Mortality - Pathology - Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshSurvival Rateen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleTransarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: Results of a comparative study in 96 Chinese patientsen_US
dc.typeArticleen_US
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.emailWong, DKH:danywong@hku.hken_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityYuen, MF=rp00479en_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.identifier.authorityWong, DKH=rp00492en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0002-9270(03)00108-4en_US
dc.identifier.pmid12809846-
dc.identifier.scopuseid_2-s2.0-0038070398en_US
dc.identifier.hkuros80551-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0038070398&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume98en_US
dc.identifier.issue5en_US
dc.identifier.spage1181en_US
dc.identifier.epage1185en_US
dc.identifier.isiWOS:000183449300036-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridYuen, MF=7102031955en_US
dc.identifier.scopusauthoridChan, AOO=7403167965en_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US
dc.identifier.scopusauthoridHui, CK=7202876933en_US
dc.identifier.scopusauthoridOoi, GC=7006176119en_US
dc.identifier.scopusauthoridTso, WK=7006905486en_US
dc.identifier.scopusauthoridYuan, HJ=7402446707en_US
dc.identifier.scopusauthoridWong, DKH=7401535819en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats